Companies Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics (BDTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Black Diamond Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,949,854FY2023
- $2,855,111FY2024
- $2,234,919FY2025
CEO total pay was $2,234,919 in fiscal 2025, down from $2,855,111 in fiscal 2024.
FY2025: salary $667,400 · bonus $0 · stock awards $189,000 · option awards $1,006,030
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Velleca | $667,400 | $0 | $189,000 | $1,006,030 | $348,717 | $0 | $23,772 | $2,234,919 |
| President and Chief Executive Officer | ||||||||
| Sergey Yurasov | 525,600 | 0 | 189,000 | 402,348 | 212,342 | 0 | 22,806 | 1,352,097 |
| Chief Medical Officer | ||||||||
| Brent Hatzis-Schoch | 511,000 | 0 | 189,000 | 352,029 | 206,444 | 0 | 23,772 | 1,282,245 |
| Chief Operating Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Velleca | $2,234,919 | $2,855,111 | $2,949,854 | ↓ −620,192 |
| Sergey Yurasov | 1,352,097 | 1,514,820 | 1,233,684 | ↓ −162,723 |
| Brent Hatzis-Schoch | 1,282,245 | 1,405,116 | — | ↓ −122,871 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is based on a pay for performance philosophy.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Human Capital Solutions (Aon plc) |
| Clawback policy | True |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mark Velleca | RSU | — | — | — | — | — | $189,000 |
| Mark Velleca | OPTION | — | — | — | — | — | 1,006,030 |
| Sergey Yurasov | OPTION | — | — | — | — | — | 402,348 |
| Brent Hatzis-Schoch | RSU | — | — | — | — | — | 189,000 |
| Brent Hatzis-Schoch | OPTION | — | — | — | — | — | 352,029 |
| Sergey Yurasov | RSU | — | — | — | — | — | 189,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mark Velleca | $189,000 | $0 | $1,006,030 | 0.0% |
| Sergey Yurasov | 189,000 | 0 | 402,348 | 0.0% |
| Brent Hatzis-Schoch | 189,000 | 0 | 352,029 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brent Hatzis-Schoch | Option | 3,752 | 3.79 | — |
| Sergey Yurasov | Option | 31,253 | 1.69 | — |
| Brent Hatzis-Schoch | Option | 58,335 | 2.92 | — |
| Sergey Yurasov | Option | 72,919 | 2.92 | — |
| Mark Velleca | RSU | 75,000 | — | 182,250 |
| Brent Hatzis-Schoch | RSU | 75,000 | — | 182,250 |
| Sergey Yurasov | RSU | 75,000 | — | 182,250 |
| Brent Hatzis-Schoch | Option | 108,334 | 4.86 | — |
| Sergey Yurasov | Option | 121,876 | 4.86 | — |
| Brent Hatzis-Schoch | Option | 175,000 | 2.52 | — |
| Sergey Yurasov | Option | 200,000 | 2.52 | — |
| Mark Velleca | Option | 290,877 | 4.86 | — |
| Mark Velleca | Option | 437,505 | 3.55 | — |
| Mark Velleca | Option | 500,000 | 2.52 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Samarth KulkarniIndependent · Lead Independent Director · Nominating/Governance | $69,000 | $0 | $57,030 | $0 | $0 | $126,030 |
| Garry E. MenzelIndependent · Audit (Chair) · Compensation | 60,000 | 0 | 57,030 | 0 | 0 | 117,030 |
| Ali BehbahaniIndependent · Audit · Compensation (Chair) | 57,500 | 0 | 57,030 | 0 | 0 | 114,530 |
| Prakash RamanIndependent · Audit · Nominating/Governance | 51,500 | 0 | 57,030 | 0 | 0 | 108,530 |
| Shannon CampbellIndependent · Compensation · Nominating/Governance | 51,000 | 0 | 57,030 | 0 | 0 | 108,030 |
| Kapil DhingraIndependent · Nominating/Governance (Chair) | 48,000 | 0 | 57,030 | 0 | 0 | 105,030 |
| Mark A. VellecaEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $57,030 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $337,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $337,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Black Diamond Therapeutics as a peer
Companies that benchmark against BDTX
7 companies name BDTX as a compensation peer
The list of companies that name BDTX as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Black Diamond Therapeutics, Inc. | 2025 | Mark Velleca | $667,400 | $189,000 | $1,006,030 | $348,717 | $2,234,919 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-26 | 35,071,684 | 1,243,945 | 154,527 | 96.57% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-26 | 96.57%a |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Prakash Raman | Director | 2026-06-19 | A | 7,907 | $2 | $13,126 | Common | Form 4 ↗ |
| Ali Behbahani | Director | 2026-06-19 | A | 8,961 | 2 | 14,875 | Common | Form 4 ↗ |
| Kapil Dhingra | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Campbell | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry E. Menzel | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ali Behbahani | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samarth Kulkarni | Director | 2026-06-26 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ali Behbahani | Director | 2026-09-18 | A | 7,707 | 2 | 14,875 | Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-09-18 | A | 6,801 | 2 | 13,126 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (32 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Mark Velleca. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table” · page 30. As printed: 2,234,919. View filing ↗
- Section 01, Sergey Yurasov. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 1,352,097. View filing ↗
- Section 01, Brent Hatzis-Schoch. DEF 14A, filed 2026-04-29. Section “2025 Summary Compensation Table”. As printed: 1,282,245. View filing ↗
- Section 03, Mark Velleca RSU. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Velleca OPTION. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Sergey Yurasov OPTION. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Brent Hatzis-Schoch RSU. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Brent Hatzis-Schoch OPTION. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Sergey Yurasov RSU. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Samarth Kulkarni. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 126,030. View filing ↗
- Section 08, Garry E. Menzel. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 117,030. View filing ↗
- Section 08, Ali Behbahani. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 114,530. View filing ↗
- Section 08, Prakash Raman. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 108,530. View filing ↗
- Section 08, Shannon Campbell. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 108,030. View filing ↗
- Section 08, Kapil Dhingra. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 105,030. View filing ↗
- Section 08, Mark A. Velleca. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Prakash Raman 2026-06-19. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ali Behbahani 2026-06-19. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kapil Dhingra 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon Campbell 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry E. Menzel 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Prakash Raman 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ali Behbahani 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Samarth Kulkarni 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ali Behbahani 2026-09-18. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Prakash Raman 2026-09-18. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-29. Item 5.07 · say-on-pay result. As reported: 96.57% (votes for as printed: 35,071,684). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 337,000 + equity 0 + all other 0 = 337,000, summed across the director compensation table rows.
- Black Diamond Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics, Inc.'s own proxy. As printed: 2,234,919. View filing ↗